Drug Trial Radar · NCT05643573
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14,830
Actual
Start
Dec 5, 2022
Primary completion
Jan 31, 2024
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel). Atrial fibrillation is a condition of having irregular and often rapid heartbeat. It can lead to the formation of blood clots in the heart which can travel through the blood stream to plug another vessel, and like this lead to serious and life-threatening conditions, such as a stroke. A stroke occurs because the brain tissue beyond the blockage no longer receives nutrients and oxygen so that brain cells die. As strokes arising from atrial fibrillation can involve extensive areas of the brain, it is important to prevent them. Blood clots are formed in a process known as coagulation. Medications are already available to prevent the formation of blood clots. When taken by mouth (orally), they are known as oral anticoagulants (OACs) including apixaban. OACs decrease the risk of the above-mentioned serious and life-threatening conditions. The main side effect of OACs is an increase of the risk of bleeding. The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care with regard to the risk of bleeding. The main purpose of this study is to collect more data about how well asundexian works to prevent stroke and systemic embolism and how safe it is compared to apixaban in people with atrial fibrillation and at high risk for stroke. To see how well the study treatment asundexian works researchers compare: * how long asundexian works well and * how long apixaban works well after the start of the treatment. Working well means that the treatments can prevent the following from happening: * stroke and/or * systemic embolism. The study will keep collecting data until a certain number of strokes or embolisms happen in the study. To see how safe asundexian is, the researchers will compare how often major bleedings occur after taking the study treatments asundexian and apixaban, respectively. Major bleedings are bleedings that have a serious or even life-threatening impact on a person's health. The study participants will be randomly (by chance) assigned to 1 of 2 treatment groups, A and B. Dependent on the treatment group, the participants will either take the study treatment asundexian by mouth once a day or apixaban by mouth twice a day for approximately 9 - 33 months. Each participant will be in the study for approximately 9 - 34 months. There will be visits to the study site every 3 to 6 months and up to 7 phone calls. Those participants who do not want or are unable to have visits to the study site may join the study remotely in selected locations. The location name contains the abbreviation - DCT in such cases. During the study, the study team will: * take blood samples * do physical examinations * examine heart health using an electrocardiogram (ECG) * check vital signs such as blood pressure and heart rate * do pregnancy tests * ask the participants questions about their quality of life * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Conditions
- Prevention of Stroke or Systemic Embolism
- Atrial Fibrillation
Interventions
Asundexian (BAY2433334)Drug
Once a day
ApixabanDrug
5 mg or 2.5 mg, twice a day, according to product label.
Asundexian matching placeboDrug
Placebo to asundexian, once a day
Apixaban matching placeboDrug
Placebo to apixaban, twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Composite of Stroke or Systemic EmbolismTime frame: Approximately 12 months
- Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major BleedingTime frame: Approximately 12 months
- Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major BleedingTime frame: Approximately 12 months
Locations
1,069 sites in 38 countries. Site status is shown where the registry gives one.
SEC Clinical Research
Dothan, Alabama
Eastern Shore Research Institute, LLC | Fairhope, AL
Fairhope, Alabama
Mobile Heart Specialists, PC
Mobile, Alabama
University of South Alabama Medical Center
Mobile, Alabama
Arkansas Cardiology | Little Rock
Little Rock, Arkansas
Valley Clinical Trials, Inc. | Covina, CA
Covina, California
Science 37
Culver City, California
University of California, Irvine
Irvine, California
VA Long Beach Healthcare System
Long Beach, California
VA Greater Los Angeles Healthcare System | West Los Angeles VA Medical Center - Cardiology Department
Los Angeles, California
Radin Cardiovascular Medical Group
Newport Beach, California
Amicis Research Center | Northridge, CA
Northridge, California
Cottage Health | Santa Barbara Cottage Hospital - Cardiology Department
Santa Barbara, California
NorthBay Clinical Research, LLC | Santa Rosa, CA
Santa Rosa, California
The Lundquist Institute | Cardiology Department
Torrance, California
Harbor - UCLA Medical Center
Torrance, California
Blue Coast Research Center, LLC
Vista, California
Interventional Cardiology Medical Group | West Hills, CA
West Hills, California
University of Colorado Hospital - Cardiology
Aurora, Colorado
South Denver Cardiology Associates, PC
Littleton, Colorado
Cardiology Associates of Fairfield County, P.C. | Stamford, CT
Norwalk, Connecticut
Integrity Clinical Research | Florida Premier Cardiology
Boynton Beach, Florida
Integrity Clinical Research | Cardiology Associates of South Florida
Boynton Beach, Florida
Cardiovascular & Vein Center of Florida | Bradenton, FL
Bradenton, Florida
Nova Clinical Research | Brandenton, FL
Bradenton, Florida
Clearwater Cardiovascular Associates | Clearwater, FL
Clearwater, Florida
Cardiology Consultants, PA
Daytona Beach, Florida
Cardiology Associates Research Company
Daytona Beach, Florida
Integrity Clinical Research | Heller Heart Health
Delray Beach, Florida
North Florida Foundation For Research And Education | Veterans Benefits Administration
Gainesville, Florida
Indago Research and Health Center | Hialeah, FL
Hialeah, Florida
Encore Research Group | Nature Coast Clinical Research - Inverness
Inverness, Florida
University of Florida - Jacksonville
Jacksonville, Florida
Heart Vein & Vascular | Longwood, FL
Longwood, Florida
Life Spring Research | Miami, FL
Miami, Florida
Southwest Florida Research | Naples, FL
Naples, Florida
Advanced Research for Health Improvement, LLC | Naples, FL
Naples, Florida
Cardiology Partners Clinical Research Institute | Palm Beach Gardens Office
Palm Beach Gardens, Florida
Baptist Heart and Vascular/Cardiology Consultants
Pensacola, Florida
Peace River Cardiovascular Center | Port Charlotte, FL
Port Charlotte, Florida
Showing 40 of 1,069 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.